do-me/EUR-LEX huggingface dataset:
Case C-198/19 P: Judgment of the Court (First Chamber) of 27 June 2024 – Teva UK Ltd, Teva Pharmaceuticals Europe BV, Teva Pharmaceutical Industries Ltd v European Commission, European Generic medicines Association AISBL (EGA) (Appeal – Competition – Pharmaceutical products – Market for perindopril – Article 101 TFEU – Agreements, decisions and concerted practices – Potential competition – Restriction of competition by object – Strategy to delay the market entry of generic versions of perindopril – Patent dispute settlement agreement)
Date: 2024-06-27
Institutions: Court of Justice
Subjects: alternative dispute resolution, cardiovascular disease, cartel, generic drug, market access, market approval, patent, restriction on competition








C_202404827EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/4827


12.8.2024






Judgment of the Court (First Chamber) of 27 June 2024 – Teva UK Ltd, Teva Pharmaceuticals Europe BV, Teva Pharmaceutical Industries Ltd v European Commission, European Generic medicines Association AISBL (EGA)


(Case C-198/19 P)
                (1)

(Appeal - Competition - Pharmaceutical products - Market for perindopril - Article 101 TFEU - Agreements, decisions and concerted practices - Potential competition - Restriction of competition by object - Strategy to delay the market entry of generic versions of perindopril - Patent dispute settlement agreement)
(C/2024/4827)
Language of the case: English

Parties


Appellants: Teva UK Ltd, Teva Pharmaceuticals Europe BV, Teva Pharmaceutical Industries Ltd (represented by: A. Richard and D. Tayar, avocats)

Other parties to the proceedings: European Commission (represented initially by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents, and by G. Peretz KC, and subsequently by F. Castilla Contreras and C. Vollrath, acting as Agents, and by G. Peretz KC), European Generic medicines Association AISBL (EGA)

Intervener in support of the other party: United Kingdom of Great Britain and Northern Ireland (represented initially by D. Guðmundsdóttir, acting as Agent, and subsequently by S. Fuller, acting as Agent)

Operative part of the judgment

The Court:






1.


Dismisses the appeal;










2.


Orders Teva UK Ltd, Teva Pharmaceuticals Europe BV and Teva Pharmaceutical Industries Ltd to bear their own costs and to pay those incurred by the European Commission;










3.


Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs.






(1)  
            OJ C 164, 13.5.2019.


ELI: http://data.europa.eu/eli/C/2024/4827/oj
ISSN 1977-091X (electronic edition)
Special report 09/2024: Security of the supply of gas in the EU – EU’s framework helped member states respond to the crisis but impact of some crisis-response measures cannot be demonstrated
Date: 2024-06-27
Institutions: European Court of Auditors
Subjects: EU energy policy, energy crisis, energy diversification, gas, gas supply, natural gas, price of energy, security of supply, self-sufficiency in energy, storage of hydrocarbons








C_202403937EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/3937


27.6.2024






Special report 09/2024:

            ‘Security of the supply of gas in the EU – EU’s framework helped member states respond to the crisis but impact of some crisis-response measures cannot be demonstrated’
         
(C/2024/3937)

The European Court of Auditors has published its special report 09/2024: ‘Security of the supply of gas in the EU – EU’s framework helped member states respond to the crisis but impact of some crisis-response measures cannot be demonstrated’.
The report can be consulted directly or downloaded at the European Court of Auditors’ website:

https://www.eca.europa.eu/en/publications/sr-2024-09



ELI: http://data.europa.eu/eli/C/2024/3937/oj
ISSN 1977-091X (electronic edition)
Case T-320/24: Action brought on 27 June 2024 – WS v EUIPO
Date: 2024-06-27
Institutions: General Court
Subjects: access to EU information, competition (EU), coronavirus disease, epidemic, recruitment








C_202404973EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/4973


19.8.2024






Action brought on 27 June 2024 – WS v EUIPO


(Case T-320/24)

(C/2024/4973)
Language of the case: English

Parties


Applicant: WS (represented by: H. Tettenborn, lawyer)

Defendant: European Union Intellectual Property Office

Form of order sought

The applicant claims that the Court should:






—


Annul the decision of EUIPO to reject the applicant’s requests of 01/03/2024 for access to the written exams in several online selection procedures (during the COVID-19 restrictions) pursuant to Regulation (EC) No 1049/2001; (1)











—


Order EUIPO to pay the procedural costs.





Pleas in law and main arguments

In support of the action, the applicant relies on a single plea in law, alleging that EUIPO breached its obligation of complying with Articles 2(1), 7(1) and 8(1) of Regulation (EC) No 1049/2001.






—


The applicant backs his claim especially by submitting that the EUIPO did not reply to his two requests for access to documents and not even acknowledge their receipt, and that EUIPO also did not reply (and also not acknowledge receipt) to his two corresponding confirmatory applications, thus breaching its obligation under Article 2(1) and its obligations under Articles 7(1) and 8(1) of Regulation (EC) No 1049/2001.






(1)  Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43).


ELI: http://data.europa.eu/eli/C/2024/4973/oj
ISSN 1977-091X (electronic edition)
Case C-197/19 P: Judgment of the Court (First Chamber) of 27 June 2024 – Mylan Laboratories Ltd, Mylan Inc. v European Commission (Appeal – Competition – Pharmaceutical products – Market for perindopril – Article 101 TFEU – Agreements, decisions and concerted practices – Potential competition – Restriction of competition by object – Strategy to delay the market entry of generic versions of perindopril – Patent dispute settlement agreement)
Date: 2024-06-27
Institutions: Court of Justice
Subjects: alternative dispute resolution, cardiovascular disease, cartel, generic drug, market access, market approval, patent, restriction on competition








C_202404826EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/4826


12.8.2024






Judgment of the Court (First Chamber) of 27 June 2024 – Mylan Laboratories Ltd, Mylan Inc. v European Commission


(Case C-197/19 P)
                (1)

(Appeal - Competition - Pharmaceutical products - Market for perindopril - Article 101 TFEU - Agreements, decisions and concerted practices - Potential competition - Restriction of competition by object - Strategy to delay the market entry of generic versions of perindopril - Patent dispute settlement agreement)
(C/2024/4826)
Language of the case: English

Parties


Appellants: Mylan Laboratories Ltd, Mylan Inc. (represented initially by C. Firth, C. Humpe and S. Kon, Solicitors, and V. Adamis, avocat, and subsequently by C. Firth, C. Humpe and S. Kon, Solicitors)

Other party to the proceedings: European Commission (represented initially by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents, and by S. Kingston, Senior Counsel, and subsequently by F. Castilla Contreras, J. Norris and C. Vollrath, acting as Agents)

Intervener in support of the other party to the proceedings: United Kingdom of Great Britain and Northern Ireland (represented initially by D. Guðmundsdóttir, acting as Agent, and subsequently by S. Fuller, acting as Agent)

Operative part of the judgment

The Court:






1.


Dismisses the appeal;










2.


Orders Mylan Laboratories Ltd and Mylan Inc. to bear their own costs and to pay the costs incurred by the European Commission;










3.


Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs.






(1)  
            OJ C 164, 13.5.2019.


ELI: http://data.europa.eu/eli/C/2024/4826/oj
ISSN 1977-091X (electronic edition)
Case C-166/19 P: Judgment of the Court (First Chamber) of 27 June 2024 – Unichem Laboratories Ltd v European Commission (Appeal – Competition – Pharmaceutical products – Market for perindopril – Article 101 TFEU – Agreements, decisions and concerted practices – Potential competition – Restriction of competition by object – Strategy to delay the market entry of generic versions of perindopril – Patent dispute settlement agreement)
Date: 2024-06-27
Institutions: Court of Justice
Subjects: alternative dispute resolution, cardiovascular disease, cartel, generic drug, market access, market approval, patent, restriction on competition








C_202404824EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/4824


12.8.2024






Judgment of the Court (First Chamber) of 27 June 2024 – Unichem Laboratories Ltd v European Commission


(Case C-166/19 P)
                (1)

(Appeal - Competition - Pharmaceutical products - Market for perindopril - Article 101 TFEU - Agreements, decisions and concerted practices - Potential competition - Restriction of competition by object - Strategy to delay the market entry of generic versions of perindopril - Patent dispute settlement agreement)
(C/2024/4824)
Language of the case: English

Parties


Appellant: Unichem Laboratories Ltd (represented initially by F. Carlin, Barrister, M. Healy, S. Mobley and H. Sheraton, Solicitors, B. Hoorelbeke, advocaat, and A. Robertson KC, and subsequently by F. Carlin, Barrister, S. Mobley and H. Sheraton, Solicitors, B. Hoorelbeke, advocaat, and A. Robertson KC)

Other party to the proceedings: European Commission (represented initially by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents, and by S. Kingston, Senior Counsel, and subsequently by F. Castilla Contreras, B. Mongin, J. Norris and C. Vollrath, acting as Agents, and lastly by F. Castilla Contreras, J. Norris and C. Vollrath, acting as Agents)

Intervener in support of the other party: United Kingdom of Great Britain and Northern Ireland, (represented initially by D. Guðmundsdóttir, acting as Agent, and subsequently by S. Fuller, acting as Agent)

Operative part of the judgment

The Court:






1.


Dismisses the appeal;










2.


Orders Unichem Laboratories Ltd to bear its own costs and to pay the costs incurred by the European Commission;










3.


Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs.






(1)  
            OJ C 148, 29.4.2019.


ELI: http://data.europa.eu/eli/C/2024/4824/oj
ISSN 1977-091X (electronic edition)
European Council Decision (EU) 2024/1862 of 27 June 2024 proposing to the European Parliament a candidate for President of the Commission
Date: 2024-06-27
Institutions: European Council
Subjects: European election, President of the Commission, announcement of candidacy








L_202401862EN.000101.fmx.xml












Official Journal of the European Union


EN
L series













2024/1862


1.7.2024







            EUROPEAN COUNCIL DECISION (EU) 2024/1862
         
of 28 June 2024
         
proposing to the European Parliament a candidate for President of the Commission


THE EUROPEAN COUNCIL,

Having regard to the Treaty on European Union, and in particular Article 17(7) thereof,

Whereas:







(1)


Article 17(7) of the Treaty on European Union provides that, taking into account the elections to the European Parliament and after having held the appropriate consultations, the European Council proposes to the European Parliament a candidate for President of the European Commission.












(2)


The elections to the European Parliament were held between 6 and 9 June 2024, in accordance with Article 11(2), first subparagraph, of the Act concerning the election of the members of the European Parliament by direct universal suffrage (1).












(3)


In accordance with Declaration No 11 annexed to the Final Act of the Intergovernmental Conference which adopted the Treaty of Lisbon (2), representatives of the European Parliament and of the European Council conducted the necessary consultations.












(4)


A candidate for President of the Commission should therefore be proposed to the European Parliament,





HAS ADOPTED THIS DECISION:



Article 1
Ms Ursula VON DER LEYEN is hereby proposed to the European Parliament as candidate for President of the Commission.


Article 2
This Decision shall be forwarded to the European Parliament.


Article 3
This Decision shall enter into force on the date of its adoption. It shall be published in the Official Journal of the European Union.




Done at Brussels, 28 June 2024.


For the European Council


The President

C. MICHEL
            





(1)  Act concerning the election of the members of the European Parliament by direct universal suffrage, annexed to Council Decision 76/787/ECSC, EEC, Euratom of 20 September 1976 (OJ L 278, 8.10.1976, p. 5).

(2)  
            OJ C 326, 26.10.2012, p. 344.


ELI: http://data.europa.eu/eli/dec/2024/1862/oj
ISSN 1977-0677 (electronic edition)
Non-opposition to a notified concentration (Case M.11581– APOLLO / PURMO)
Date: 2024-06-27
Institutions: Directorate-General for Competition, European Commission
Subjects: air conditioning, building industry, economic concentration, heating, investment company, merger control, pension scheme, piping, software, thermal equipment








C_202404348EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/4348


3.7.2024






Non-opposition to a notified concentration
(Case M.11581– APOLLO / PURMO)
(Text with EEA relevance)
(C/2024/4348)

On 27 June 2024, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:






—


in the merger section of the ‘Competition policy’ website of the Commission (https://competition-cases.ec.europa.eu/search). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,










—


in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32024M11581. EUR-Lex is the online point of access to European Union law.






(1)  
            OJ L 24, 29.1.2004, p. 1.


ELI: http://data.europa.eu/eli/C/2024/4348/oj
ISSN 1977-091X (electronic edition)
Case C-164/19 P: Judgment of the Court (First Chamber) of 27 June 2024 – Niche Generics Ltd v European Commission (Appeal – Competition – Pharmaceutical products – Market for perindopril – Article 101 TFEU – Agreements, decisions and concerted practices – Potential competition – Restriction of competition by object – Strategy to delay the market entry of generic versions of perindopril – Patent dispute settlement agreement)
Date: 2024-06-27
Institutions: Court of Justice
Subjects: alternative dispute resolution, cardiovascular disease, cartel, generic drug, market access, market approval, patent, restriction on competition








C_202404823EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/4823


12.8.2024






Judgment of the Court (First Chamber) of 27 June 2024 – Niche Generics Ltd v European Commission


(Case C-164/19 P)
                (1)

(Appeal - Competition - Pharmaceutical products - Market for perindopril - Article 101 TFEU - Agreements, decisions and concerted practices - Potential competition - Restriction of competition by object - Strategy to delay the market entry of generic versions of perindopril - Patent dispute settlement agreement)
(C/2024/4823)
Language of the case: English

Parties


Appellant: Niche Generics Ltd (represented initially by F. Carlin, Barrister, M. Healy, S. Mobley and H. Sheraton, Solicitors, B. Hoorelbeke, advocaat, and A. Robertson KC, and subsequently by F. Carlin, Barrister, S. Mobley and H. Sheraton, Solicitors, B. Hoorelbeke, advocaat, and A. Robertson KC)

Other party to the proceedings: European Commission (represented initially by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents, and by S. Kingston, Senior Counsel, and subsequently by F. Castilla Contreras, B. Mongin, J. Norris and C. Vollrath, acting as Agents, and lastly by F. Castilla Contreras, J. Norris and C. Vollrath, acting as Agents)

Intervener in support of the other party to the proceedings: United Kingdom of Great Britain and Northern Ireland (represented initially by D. Guðmundsdóttir, acting as Agent, and subsequently by S. Fuller, acting as Agent)

Operative part of the judgment

The Court:






1.


Dismisses the appeal;










2.


Orders Niche Generics Ltd to bear its own costs and to pay the costs incurred by the European Commission;










3.


Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs.






(1)  
            OJ C 148, 29.4.2019.


ELI: http://data.europa.eu/eli/C/2024/4823/oj
ISSN 1977-091X (electronic edition)
Prior notification of a concentration (Case M.11576 – KKR / NEXEYE) – Candidate case for simplified procedure
Date: 2024-06-27
Institutions: Directorate-General for Competition, European Commission
Subjects: Austria, Belgium, Germany, Netherlands, Sweden, economic concentration, investment company, medical device, merger control, optical industry, retail trade








C_202404140EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/4140


27.6.2024






Prior notification of a concentration
(Case M.11576 – KKR / NEXEYE)
Candidate case for simplified procedure
(Text with EEA relevance)
(C/2024/4140)


1.   
On 19 June 2024, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


KKR & Co. Inc. (together with its subsidiaries, ‘KKR’) (United States),










—


Nexeye Holding B.V. (‘Nexeye’) (the Netherlands)




KKR will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Nexeye.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


KKR is a global investment firm that offers alternative asset management as well as capital markets and insurance solutions,










—


Nexeye is an optical and hearing aids retailer headquartered in the Netherlands, with activities in Austria, Belgium, Germany, the Netherlands, and Sweden. Nexeye consists of three value-for-money options brands (Hans Anders, Eyes + More, and Direkt Optik), operating in the five EEA Member States.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11576 – KKR / NEXEYE
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  
            OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  
            OJ C 160, 5.5.2023, p. 1.


ELI: http://data.europa.eu/eli/C/2024/4140/oj
ISSN 1977-091X (electronic edition)
Notice for the attention of a person subject to the restrictive measures provided for in Council Decision 2014/145/CFSP and Council Regulation (EU) No 269/2014 concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of Ukraine
Date: 2024-06-27
Institutions: Council of the European Union
Subjects: EU restrictive measure, Russia, Russo-Ukrainian issue, Ukraine, economic sanctions, international sanctions, natural person, territorial dispute, territorial law








C_202404263EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/4263


27.6.2024






Notice for the attention of a person subject to the restrictive measures provided for in Council Decision 2014/145/CFSP and Council Regulation (EU) No 269/2014 concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of Ukraine
(C/2024/4263)

The following information is brought to the attention of Boris Viktorovich OBNOSOV (No. 1600), person appearing in the Annex to Council Decision 2014/145/CFSP (1) and in Annex I to Council Regulation (EU) No 269/2014 (2) concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of Ukraine.
The Council envisages maintaining the restrictive measures against the above-mentioned person with new statements of reasons and information. This person is hereby informed that he may submit a request to the Council to obtain the information related to the maintaining of restrictive measures, before 4 July 2024, to the following address:





Council of the European Union




General Secretariat




RELEX.1




Rue de la Loi/Wetstraat 175




1048 Bruxelles/Brussel




BELGIQUE/BELGIË




Email: sanctions@consilium.europa.eu







(1)  
            OJ L 78, 17.3.2014, p. 16.

(2)  
            OJ L 78, 17.3.2014, p. 6.


ELI: http://data.europa.eu/eli/C/2024/4263/oj
ISSN 1977-091X (electronic edition)
Joined Cases C-511/22 and C-529/22, trendtours Touristik: Order of the President of the Court of 27 June 2024 (requests for a preliminary ruling from the Landgericht Frankfurt am Main – Germany) – AQ (C-511/22), PA (C-529/22) v trendtours Touristik GmbH
Date: 2024-06-27
Institutions: Court of Justice
Subjects: consumer protection, package travel, provision of services, termination of a contract, traveller








C_202405793EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/5793


7.10.2024






Order of the President of the Court of 27 June 2024 (requests for a preliminary ruling from the Landgericht Frankfurt am Main – Germany) – AQ (C-511/22), PA (C-529/22) v trendtours Touristik GmbH


(Joined Cases C-511/22 and C-529/22,
                (1)
trendtours Touristik)

(C/2024/5793)
Language of the case: German
The President of the Court has ordered that the cases be removed from the register.


(1)  
            OJ C 441, 21.11.2022.


ELI: http://data.europa.eu/eli/C/2024/5793/oj
ISSN 1977-091X (electronic edition)